Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Heart failure

Novel approach leads to improvement in myocardial and vascular function

    • Cardiology
    • Congress Reports
    • Market & Medicine
    • RX
  • 2 minute read

In 2021, the European Society of Cardiology’s Heart Failure Guidelines Task Force published new guidelines mentioning heart failure exacerbations for the first time and emphasizing the urgency of accelerating the adoption of basic therapies. Such deterioration is usually accompanied by decompensation and heart failure-related hospitalization with i.v. therapy [1].

New terminology has been introduced in the universal definition of heart failure (HF) (e.g., the use of “remission” instead of “recovered”). This definition emphasized that worsening heart failure means worsening signs and symptoms despite ongoing therapy for HF. Therefore, it is important to monitor patients for worsening of the condition (e.g., worsening of HF symptoms despite ongoing therapy) and to rapidly optimize the patient’s treatment regimen after hospitalization and/or worsening of the condition.

Vericiguat as a novel treatment approach

Many traditional therapies work by inhibiting signaling pathways. Vericiguat is a therapeutic agent that acts by stimulating soluble guanylate cyclase (sGC). This novel approach to heart failure results in improved myocardial and vascular function [1–3]. The therapeutic agent is well tolerated by patients with chronic heart failure with reduced ejection fraction after decompensation of heart failure. Vericiguat plus baseline therapy significantly reduced the risk of cardiovascular death or hospitalization due to heart failure in adults with symptomatic chronic heart failure and with reduced ejection fraction after decompensation compared with placebo plus baseline therapy [3]. Recent therapeutic advances and implementation of new guidelines may allow HF patients to reduce or avoid hospitalizations and maintain their quality of life.

Source: Annual Bayer Pharma Media Day 2022

 

Literature:

  1. Bozkurt B, et al: Universal Definition and Classification of Heart Failure. JCF. 2021 Journal of Cardiac Failure, 27(4), pp.387-413. www.onlinejcf.com/article/S1071-9164(21)00050-6/fulltext.
  2. Armstrong PW, et al: Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020; 382(20): 1952-1953.
  3. Boettcher M et al: Pharmacodynamic and pharmacokinetic interaction profile of vericiguat. Poster P1183. Heart Failure Congress of the European Society of Cardiology, May 25-28, 2019.

 

CARDIOVASC 2022; 21(2): 38

Autoren
  • Isabell Bemfert
Publikation
  • CARDIOVASC
Related Topics
  • Heart failure
  • HF
Previous Article
  • Advanced training

Launch event for interdisciplinary training on new treatment in ulcerative colitis

  • Gastroenterology and Hepatology
  • General Internal Medicine
  • RX
  • Training with partner
View Post
Next Article
  • From the clinic - De la clinique

Case reports from Germany -Rapports de cas d’Allemagne

  • Partner Content
  • RX
View Post
You May Also Like
View Post
  • 7 min
  • From genome profiles to targeted therapies

Advances in breast cancer therapy in the age of molecular diagnostics

    • Education
    • Genetics
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 6 min
  • Current overview of evidence, mechanisms and clinical implications

Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 12 min
  • Parkinson's disease

Individual therapy management for an optimized outcome – an update

    • CME continuing education
    • Neurology
    • RX
    • Studies
    • Training with partner
View Post
  • 7 min
  • Rare pulmonary syndromes

Yellow nail and Swyer-James syndrome

    • CME continuing education
    • Dermatology and venereology
    • General Internal Medicine
    • Infectiology
    • Pneumology
    • RX
View Post
  • 6 min
  • Latent autoimmune diabetes in adults (LADA)

Looks like type 2, but is type 1

    • Cases
    • Education
    • Endocrinology and Diabetology
    • RX
    • Studies
View Post
  • 6 min
  • Treatment of vitiligo

Focus on patient perspective and disease activity

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 5 min
  • Vaccine-preventable respiratory diseases

RSV and pneumococci: recommendations for risk groups

    • Congress Reports
    • General Internal Medicine
    • Infectiology
    • Pediatrics
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 5 min
  • Circadian rhythm in asthma

Chronotherapy can improve control

    • Allergology and clinical immunology
    • General Internal Medicine
    • Pneumology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Yellow nail and Swyer-James syndrome
  • 2
    Individual therapy management for an optimized outcome – an update
  • 3
    Doing sport without fear or risk
  • 4
    UV protection and skin cancer screening – Update 2025
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.